Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Improving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program.

Tekinturhan E, Audureau E, Tavolacci MP, Garcia-Gonzalez P, Ladner J, Saba J.

BMC Health Serv Res. 2013 Aug 10;13:304. doi: 10.1186/1472-6963-13-304.

2.

Increasing access to care for chronic myeloid leukemia patients: assessment of a scaling-up program.

Ladner J, Tekinturhan E, Tavolacci MP, Audureau E, Saba J.

J Health Care Poor Underserved. 2013 Nov;24(4):1486-97. doi: 10.1353/hpu.2013.0160.

PMID:
24185146
3.

Ongoing challenges of a global international patient assistance program.

Lassarat S, Jootar S.

Ann Oncol. 2006 Jun;17 Suppl 8:viii43-viii46.

PMID:
16801339
5.

International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted nations.

Sadak KT, Fultz K, Mendizabal A, Reaman G, Garcia-Gonzalez P, Levine PH.

Pediatr Blood Cancer. 2014 Oct;61(10):1774-8. doi: 10.1002/pbc.25120. Epub 2014 Jun 29.

PMID:
24976310
6.
7.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
8.

The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.

Li Y, Meng X.

Ann R Coll Surg Engl. 2015 Apr;97(3):215-20. doi: 10.1308/003588414X14055925061432.

9.

Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.

Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.

Health Technol Assess. 2005 Jul;9(25):1-142. Review.

10.

Cultural factors related to adherence to imatinib in CML: a Mexican perspective.

Cantú-Rodríguez OG, Sánchez-Cárdenas M, Gutiérrez-Aguirre CH, Jaime-Pérez JC, Mancias-Guerra C, González-Llano O, Gómez-Almaguer D.

Hematology. 2015 Mar;20(2):72-6. doi: 10.1179/1607845414Y.0000000165. Epub 2014 Jul 18.

PMID:
25034734
11.

[Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].

Raccah E, Merimsky O, Kuten A, Apter S, Catane R.

Harefuah. 2007 May;146(5):329-34, 408. Hebrew.

PMID:
17674545
12.

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators.

Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

13.

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Woźniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA, Limon J.

BMC Cancer. 2012 Mar 22;12:107. doi: 10.1186/1471-2407-12-107.

14.

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL.

Ann Surg Oncol. 2012 Apr;19(4):1074-80. doi: 10.1245/s10434-011-2190-5. Epub 2011 Dec 28. Erratum in: Ann Surg Oncol. 2012 Jul;19(7):2420.

15.

Regional variations in age at diagnosis and overall survival among patients with chronic myeloid leukemia from low and middle income countries.

Mendizabal AM, Garcia-Gonzalez P, Levine PH.

Cancer Epidemiol. 2013 Jun;37(3):247-54. doi: 10.1016/j.canep.2013.01.002. Epub 2013 Feb 12.

PMID:
23411044
16.
17.
18.
19.

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD, Blanke CD, von Mehren M, Brennan MF, McCall L, Ota DM, DeMatteo RP; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant Gist Study Team.

J Am Coll Surg. 2012 Jul;215(1):53-9; discussion 59-60. doi: 10.1016/j.jamcollsurg.2012.05.008.

20.

Supplemental Content

Support Center